More on The Weave
I covered my $CRWV short between $62 AND $63 on Sunday night – as reported.
Positions: None.
I covered my $CRWV short between $62 AND $63 on Sunday night – as reported.
Positions: None.
If the negative pattern develops, I’d be quick to hit the sell button.
– $RAPP +26% (Phase 2 RAP-219 trial met the primary and secondary endpoints in bipolar mania)
– $MSCI +5.9% (Q3 earnings and revenue topped expectations)
– $EFX +5.5% (sharply positive initial reaction to Q3 results released before the bell)
– $HTZ +5.0% (Oro Mobility secured an $80 million strategic equity investment to accelerate its standalone growth)
– $HAL +4.4% (Q3 earnings and revenue beat expectations)
– $SNY +2.4% (no clear fresh catalyst identified; unusually strong, liquid ADR move)
– $APA +1.9%, $XOM +1.2%, $CVX +1.4%, $COP +1.5%, $OXY +1.6%, $SLB +1.4% (energy names rise as crude jumps on renewed Middle East supply risks)
– $VICR +1.7% (Q3 product and royalty revenue surged and gross margin expanded sharply)
– $GM -7.6% (Q3 beat, but the full-year profit range was narrowed with the upper end cut, disappointing expectations for another guidance raise)
– $GPC -6.3% (quarter narrowly beat, but the full-year earnings range was narrowed and its upper end cut)
– $STLD -5.4% (Q3 profit missed consensus and fell below the company’s own guidance despite a revenue beat)
– $AAOI -4.6%, SKHY -4.8%, COHR -3.5%, SNDK -3.2%, MU -2.7%, LITE -2.7% (AI hardware, memory and optical names fall as renewed bubble concerns and a weak Korean AI listing pressure the trade)
– $CCK -4.3% (Q3 reaction turns negative as rising input costs offset strong beverage-can volume growth)
– $CRWV -3.9%, NBIS -4.4%, IREN -4.3% (debt-heavy AI-infrastructure names fall as borrowing-cost and funding concerns deepen)
– $GE -3.6% (Q3 beat and the outlook was raised, but shares slip in a high-expectations sell-the-news reaction)
– $BHP -3.0% (quarterly copper production fell 19% on lower grades, maintenance and operational disruptions)
– $AAPL -1.4% (Loop Capital downgrades to Hold from Buy and cuts its target on weaker iPhone shipment expectations)
Seventy percent of active managers are trailing their benchmarks, and the pressure to catch up could trigger a focus on stock picking.
The megacap growth sectors went from worst (Friday) to first (Monday) as chipmakers snapped an eight-session losing streak, but rising Treasury yields left seven sectors, the Dow Jones Industrial Average, and the equal-weight S&P 500 lower.
We got a whiff of panic, now what if real fear pushes up the VIX?
– $IRON +52% (Phase 3 APOLLO trial met all primary and secondary endpoints in erythropoietic protoporphyria)
– $AAME +41% (long-delayed 2025 annual report was filed, showing a return to annual profitability)
– $XLAB +24% (extends rally after securing an $8.2M AI-server order)
– $TCRT +20% (extends volatile rally tied to a proposed acquisition and financing of up to $350M)
– $MEDS +15% (extends rally after outlining peptide-compounding expansion and licensing a direct-to-consumer GLP-1 platform)
– $CLF +11% (Q3 profit and EBITDA beat expectations, Q4 EBITDA was guided higher and 2027 EBITDA is expected to exceed $4B)
– $NBIS +7.5%, $CRWV +7.7%, $BE +5.2%, $SMCI +4.1%, $IREN +5.9% (AI-infrastructure names rebound from last week’s financing-driven selloff as Treasury yields ease)
– $CRDO +4.7%, $TER +5.1%, $LRCX +4.6%, $AMD +3.7%, $MU +3.7%, $AVGO +3.1% (chip names rebound from last week’s AI-led selloff ahead of key sector earnings)
– $INTC +4.3% (JPMorgan upgrades to Neutral from Underweight as confidence in the turnaround improves)
– $VAI +4.0% (agrees to acquire an 18MW Ohio computing center)
– $DDOG +3.9% (Bernstein upgrades to Outperform and sharply raises its price target on stronger AI-consumption trends)
– $ACTU -9.1% (files to sell 40M shares with 20M warrants)
Another selloff in AI names broadened to encompass most of Tech, sending the Nasdaq-100 to its worst week since April 2025. Five sectors though would finish the week up 2% or more, as 30-year Treasury yields fell the most since April 2025.
We put capital to work in two holdings, exited another and bumped up our price target for a long-time position.
Here’s why I’m getting into this ‘boring’ insurance play and a biotech name.